- Home
- ELWS vs MYNZ Comparison
ELWS vs MYNZ Comparison
Compare ELWS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- MYNZ
- Stock Information
- Founded
- ELWS 2018
- MYNZ 2021
- Country
- ELWS Japan
- MYNZ Germany
- Employees
- ELWS N/A
- MYNZ N/A
- Industry
- ELWS
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- MYNZ Health Care
- Exchange
- ELWS Nasdaq
- MYNZ Nasdaq
- Market Cap
- ELWS 6.0M
- MYNZ 7.0M
- IPO Year
- ELWS 2023
- MYNZ 2021
- Fundamental
- Price
- ELWS $1.90
- MYNZ $2.44
- Analyst Decision
- ELWS
- MYNZ Buy
- Analyst Count
- ELWS 0
- MYNZ 2
- Target Price
- ELWS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- ELWS 187.7K
- MYNZ 310.7K
- Earning Date
- ELWS 06-03-2025
- MYNZ 05-27-2025
- Dividend Yield
- ELWS N/A
- MYNZ N/A
- EPS Growth
- ELWS N/A
- MYNZ N/A
- EPS
- ELWS N/A
- MYNZ N/A
- Revenue
- ELWS $2,292,406.00
- MYNZ $893,991.00
- Revenue This Year
- ELWS N/A
- MYNZ $42.95
- Revenue Next Year
- ELWS N/A
- MYNZ N/A
- P/E Ratio
- ELWS N/A
- MYNZ N/A
- Revenue Growth
- ELWS 404.13
- MYNZ N/A
- 52 Week Low
- ELWS $1.04
- MYNZ $0.18
- 52 Week High
- ELWS $8.68
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- ELWS 46.25
- MYNZ 37.09
- Support Level
- ELWS $1.78
- MYNZ $2.18
- Resistance Level
- ELWS $3.67
- MYNZ $2.57
- Average True Range (ATR)
- ELWS 0.30
- MYNZ 0.31
- MACD
- ELWS 0.01
- MYNZ -0.01
- Stochastic Oscillator
- ELWS 6.08
- MYNZ 12.04
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.